Larry L. Wood - 05 Jul 2022 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role: CVP, TAVR
Signature: Linda J. Park, Attorney-in-Fact
Issuer symbol: EW
Transactions as of: 05 Jul 2022
Net transactions value: -$428,343
Form type: 4
Filing time: 05 Jul 2022, 20:59:17 UTC
Previous filing: 01 Jun 2022
Next filing: 09 Aug 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EW	Common Stock	Options Exercise	$266,144	+7,242	+3.6%	$36.75	209,474	05 Jul 2022	Direct	F1
transaction	EW	Common Stock	Sale	$694,486	-7,242	-3.5%	$95.90	202,232	05 Jul 2022	Direct	F1, F2
holding	EW	Common Stock						496	05 Jul 2022	401(k)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EW	Employee Stock Option (Right to Acquire)	Options Exercise	$0	-7,242	-17%	$0.000000	36,204	05 Jul 2022	Common Stock	7,242	$36.75	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2021.
F2	This transaction was executed in multiple trades at prices ranging from $95.205 to $95.910. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.